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Abstract
Background. Immunoglobulin A nephropathy (IgAN) is
the most common form of glomerulonephritis, and a sub-
stantial number of patients succumb to end-stage renal dis-
ease (ESRD). However, prediction of the renal outcome
in individual patients remains difficult. We have already
published a scoring system using the data in a prospective
cohort of IgAN patients followed up from 1995 to 2002.
Methods. The cohort was further followed up until 2005 in
97 clinical units in Japan. The data from 2283 patients were
analysed by Cox regression to determine the predictors of
ESRDinIgAN,andtheirβ-coefficientswereconvertedinto
scores to estimate ESRD risk within 10 years.
Results. During the follow-up (median, 87 months),
252 patients developed ESRD. Male sex, age less than
30 years, family histories of chronic renal failure and
chronicglomerulonephritis,hypertension,proteinuria,mild
haematuria, hypoalbuminaemia, low glomerular filtration
rate and a high histological grade at initial renal biopsy
were associated with the risk of ESRD in the multivari-
able analysis. A scoring system was framed to estimate
the 10-year ESRD risk using eight variables significant in
both univariable and multivariable models. This prognostic
scoreaccuratelyclassifiedpatientsbyrisk:patientswithes-
timates of 0–4.9, 5.0–19.9, 20.0–49.9 and 50.0–100% had
an observed incidence of 1.7, 8.3, 36.7 and 85.5%, respec-
tively. The corresponding area under the receiver-operating
characteristic curve was 0.942 (95% confidence interval,
0.925–0.958).
Conclusion.Thisvalidatedscoringsystemtoquantitatively
estimate ESRD risk during the 10-year follow-up of IgAN
patients will serve as a useful prognostic tool in clinical
practice.
Keywords: cohort studies; IgA nephropathy; prognosis; renal dialysis;
risk factors
Introduction
Immunoglobulin A nephropathy (IgAN) was described as
a new clinical entity in 1968 by Berger and Hinglais [1],
and is now the most common cause of idiopathic glomeru-
lonephritis [2–4]. Long-term outcomes and prognostic fac-
tors of patients with IgAN have been evaluated in many
studies. Although this disorder is thought to follow a be-
nign course, many patients are at a risk of at least slow
progression. Furthermore, end-stage renal disease (ESRD)
developed in ∼15% of cases within 10 years [5].
Several tools have been available to estimate the renal
prognosis using various clinical and pathological factors
[6–9]. However, one was based on a relatively small size
cohort [6], another used surrogate endpoints such as an in-
creaseinserumcreatinine[7]andtheothersdidnotprovide
quantitative estimates of the ESRD risks [8,9].
We earlier proposed a valid scoring system to quantita-
tively predict renal outcomes based on the 7-year follow-up
data involving more than 2000 patients with biopsy-proven
IgAN [10]. However, renal function deteriorates so slowly
in the early stage of IgAN that the longer the follow-up
period, the more useful in the clinical settings is the con-
structed prediction model [7]. We, therefore, extended the
follow-up of this cohort for 3 more years and refined the
scoring system to predict renal outcomes at 10 years.
Methods
The details of the methods used here were described in our earlier 7-year
follow-up study [10]. Briefly, 2450 patients with biopsy-proven IgAN
from 97 clinical units were followed up from 1995 when a nationwide
survey on IgAN was jointly conducted by the two research committees for
the specified intractable diseases organized by the Japanese Government.
Follow-up mail surveys to collect information on outcomes such as death,
ESRD and serum creatinine were performed in 1997, 1999 and 2002 with
response rates of 82.5, 95.7 and 93.3%, respectively. An additional survey
was carried out in 2005 (response rate, 82.7%).
The baseline data of the patients were obtained by reviewing medical
records in the nationwide survey in 1995. The data included sex, age,
family history of chronic renal failure and chronic glomerulonephritis,
initial clinical manifestations, year of diagnostic renal biopsy, systolic
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Table 1. Criteria for histological grading from the Joint Committee of the Research Group on Progressive Renal Disease (Ministry of Health and
Welfare of Japan) and the Japanese Society of Nephrology [12]
Grade Glomerular findings Interstitial and vascular findings
I Slight mesangial cell proliferation and increased matrix. Prominent changes are not seen in the interstitium, renal tubuli or
blood vessels. Glomerulosclerosis, crescent formation or adhesion to
Bowman’s capsule is not observed.
II Slight mesangial cell proliferation and increased matrix. Same as above.
Glomerulosclerosis, crescent formation or adhesion to
Bowman’s capsule seen in <10% of all biopsied
glomeruli.
III Moderate, diffuse mesangial cell proliferation and
increased matrix.
Cellular infiltration is slight in the interstitium except around some
sclerosed glomeruli. Tubular atrophy is slight, and mild vascular
sclerosis is observed. Glomerulosclerosis crescent formation or adhesion to
Bowman’s capsule seen in 10–30% of all biopsied
glomeruli.
IV Severe, diffuse mesangial cell proliferation and
increased matrix.
Interstitial cellular infiltration and tubular atrophy, as well as
fibrosis are seen. Hyperplasia or degeneration may be seen in some
intrarenal arteriolar walls. Glomerulosclerosis, crescent formation or adhesion to
Bowman’s capsule seen in >30% of all biopsied
glomeruli. When sites of sclerosis are totalled and
converted to global sclerosis, the sclerosis rate is >50%
of all glomeruli. Some glomeruli also show
compensatory hypertrophy.
The sclerosis rate is the most important of these indices.
and diastolic blood pressure, urine protein and blood, serum total protein
and albumin and serum creatinine. Proteinuria was semiquantified with a
standard urine dipstick with (−), (±), (+), (++)a n d( +++) correspond-
ing to <10, 10–29, 30–99, 100–299 and ≥300 mg/dL of urine albumin,
respectively. For estimation of the glomerular filtration rate (GFR), the
estimation equation for Japanese patients with chronic kidney disease was
applied [11]. This equation calculates the GFR from serum creatinine, age
and gender. Histological grade at initial renal biopsy was assessed using
the criteria from the joint committee of one of the aforementioned gov-
ernmental research committees and the Japanese Society of Nephrology
(Table 1) [12]. Information on therapy was collected in 1997, 2 years after
the beginning of the follow-up.
Statistical methods
The study endpoint was ESRD defined as the initiation of chronic
haemodialysis. Since there was little influence of competing risks in the
currentstudy,thecomplementofaKaplan–Meiersurvivalestimatewasre-
ferred to as the 10-year cumulative incidence (risk) of ESRD [13]. Hazard
ratios of potential prognostic factors were estimated using the Cox propor-
tional hazards regression model. The independent effect of each variable
was assessed by multivariable analysis. Systolic or diastolic blood pres-
sure and serum total protein or albumin were included in the multivariable
model because of their close relationship with each other. Akaike’s In-
formation Criterion (AIC) and the Bayesian Information Criterion (BIC)
were used to select the most appropriate covariance structure.
Development of the scoring system
A scoring system to predict ESRD in individual patients with IgAN was
composed based on the proportional hazards model including the signif-
icant variables in the aforementioned multivariable analysis. To enhance
parsimony, only variables that possessed significant univariate relation-
ships with ESRD were included in the final scoring system [14]. To
generate a simple integer-based point score for each predictor variable,
scores were given by multiplying the β-coefficient by 10 and rounding up
or down to the nearest integer. The overall risk score for each patient was
calculatedbysummingthescoresofallcomponents.Thebaselinesurvivor
function was estimated by the Kaplan–Meier product–limit estimate.
Evaluation of the scoring system
To examine the goodness of fit of the scoring system to the data, we
divided the patients into four groups according to the predicted 10-year
risk of ESRD, that is, low (0–4.9%), moderate (5.0–19.9%), high (20.0–
49.9%) and very high (50.0–100%). The renal survival curve of ESRD
was then drawn in each group using the Kaplan–Meier method. To further
assesstheutilityofthescore,weusedtheareaunderthereceiver-operating
characteristic (ROC) curve for the 10-year risk of ESRD. The area and
its 95% confidence interval (CI) were estimated by the nonparametric
method.
As an additional analysis, one-third of the participants were randomly
allocated to a validation sample and the remainder to a derivation sam-
ple. The prognostic score was developed in the derivation sample, and
the actual 10-year cumulative incidence of ESRD was computed by the
predicted risk in the validation sample. The area under the ROC curve was
also estimated in the validation group. Considering the sampling error, we
repeated this procedure in 100 different validation sets.
StatisticalanalyseswereperformedusingtheStata10.1software(Stata
Corporation, College Station, TX, USA). All tests of significance were
two-tailed, and P-values <0.05 were considered statistically significant.
This investigation was approved by the Ethics Committee of Kyoto Uni-
versity Graduate School of Medicine and the Ethics Committee of the
Juntendo University School of Medicine.
Results
Participants’ demographic and clinical characteristics
Out of the 2450 patients tracked from 1995, 165 patients
with unknown outcomes and 2 patients with erroneous
baseline serum creatinine levels were excluded, leaving
2283 patients in the current analysis. The median age of the
included patients at baseline was 32.1 years [interquartile
range (IQR), 20.7–46.9], and 51.3% were women. During
the follow-up of 14 975 person-years [median follow-up
period, 87 months (IQR, 42–122)], 252 patients (11.0%)
developed ESRD. The renal survival rate at 10 years was
85.0% (95% CI, 83.1–86.7). Twenty-one deaths without
ESRD were also reported: six from circulatory diseases,
six from neoplasms, two from other causes and seven from
unknown causes. By 1997, 34.5%, 10.6% and 28.2% of the
patients had received corticosteroids, immunosuppressive
agents and angiotensin-converting enzyme inhibitors
(ACEi), respectively.
Table 2 summarizes the 10-year cumulative incidence of
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Table 2. Ten-year cumulative incidence of end-stage renal disease by baseline demographic and clinical characteristics and their hazard ratio
10-year
cumulative
incidence of
ESRD Hazard ratio for ESRD
Observed No. of
n person-years ESRD % 95% CI Hazard ratio 95% CI P-value
Sex
Women 1171 7926 94 11.1 9.1–13.5 1.00 –
Men 1112 7049 158 19.3 16.6–22.3 1.88 1.46–2.43 <0.001
Age (years)
∼19 530 3089 13 4.4 2.4–8.0 1.00 –
20–29 508 3195 39 10.9 8.0–14.8 2.94 1.57–5.50
30–39 368 2580 39 13.4 9.8–18.2 3.69 1.97–6.91
40–49 458 3330 75 20.2 16.4–24.8 5.53 3.07–9.98
50–59 288 1947 58 24.1 19.0–30.2 7.25 3.97–13.2
60 and above 131 834 28 26.6 18.9–36.8 8.09 4.19–15.6 <0.001 for trend
Family history of chronic renal failure
No 2189 14393 239 15.0 13.2–16.9 1.00 –
Yes 94 582 13 16.5 9.6–27.6 1.34 0.77–2.35 0.30
Family history of chronic glomerulonephritis
No 2146 14113 236 15.0 13.3–17.0 1.00 –
Yes 137 862 16 15.1 9.2–24.1 1.11 0.67–1.83 0.70
Initial manifestation
By chance in a health check-up 1588 10400 185 15.5 13.5–17.8 1.00 –
Macrohaematuria 260 1747 14 8.7 5.0–14.7 0.45 0.26–0.77 0.004
Acute nephritis 112 721 8 10.5 5.1–21.0 0.62 0.31–1.26 0.19
Nephrosis 66 421 11 24.4 13.9–40.5 1.46 0.79–2.68 0.23
Other 233 1536 33 19.1 13.7–26.2 1.21 0.83–1.75 0.32
Year of initial renal biopsy
1994–1995 481 3130 43 13.8 10.2–18.5 1.00 –
1992–1993 596 3847 62 13.9 10.9–17.7 1.18 0.80–1.74
1990–1991 403 2551 47 15.3 11.5–20.2 1.34 0.89–2.03
1988–1989 291 2057 35 16.1 11.6–22.2 1.25 0.80–1.95
1987 or before 474 3110 63 17.5 13.8–22.0 1.49 1.01–2.19 0.049 for trend
Systolic blood pressure (mmHg)
≤120 1037 6845 49 7.0 5.3–9.3 1.00 –
121–130 437 2902 51 16.6 12.7–21.5 2.45 1.66–3.63
131–140 311 2103 54 22.1 17.2–28.1 3.61 2.45–5.31
141–150 175 1075 43 31.6 24.2–40.6 5.56 3.69–8.38
151–160 77 494 17 24.0 15.2–36.6 4.83 2.78–8.38
>160 47 280 16 37.4 24.5–54.2 8.03 4.57–14.1 <0.001 for trend
Diastolic blood pressure (mmHg)
≤70 961 6225 43 6.7 4.9–9.1 1.00 –
71–80 549 3703 65 16.5 13.1–20.7 2.56 1.74–3.76
81–90 396 2591 82 25.3 20.7–30.7 4.60 3.18–6.65
91–100 150 1019 33 26.1 19.2–35.0 4.74 3.01–7.46
>100 28 160 7 32.4 16.5–57.5 6.28 2.83–14.0 <0.001 for trend
Urine protein
(−), (±) 834 5369 6 1.3 0.6–3.1 1.00 –
(+) 528 3719 30 8.1 5.6–11.5 7.28 3.03–17.5
(++) 488 3208 88 23.2 19.0–28.0 24.6 10.8–56.4
(+++) 333 2040 109 39.5 33.7–45.9 47.7 21.0–108.5 <0.001 for trend
Urine red blood cells (/high-power field)
None 582 3631 27 7.8 5.3–11.5 1.00 –
1–29 1244 8216 172 18.2 15.7–20.9 2.83 1.89–4.25
≥30 366 2550 35 12.3 8.8–17.0 1.86 1.13–3.08 0.009 for trend
Serum total protein (g/dL)
≥7.5 448 3020 14 4.8 2.8–8.1 1.00 –
7.0–7.4 764 4999 57 11.2 8.6–14.5 2.45 1.36–4.39
6.5–6.9 682 4632 81 15.6 12.6–19.2 3.77 2.14–6.65
6.0–6.4 245 1513 61 31.2 24.9–38.7 8.60 4.81–15.4
≤5.9 77 448 33 48.3 36.8–61.3 15.8 8.48–29.6 <0.001 for trend
Serum albumin (g/dL)
≥4.4 826 5427 36 6.6 4.7–9.1 1.00 –
4.2–4.3 437 2989 28 9.7 6.7–14.0 1.41 0.86–2.32
4.0–4.1 362 2529 46 15.9 12.0–20.9 2.75 1.78–4.25
3.8–3.9 229 1463 42 23.5 17.7–30.8 4.31 2.76–6.73
≤3.7 229 1379 81 41.4 34.6–49.0 8.81 5.95–13.0 <0.001 for trend
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Table 2. Continued.
10-year
cumulative
incidence of
ESRD Hazard ratio for ESRD
Observed No. of
n person-years ESRD % 95% CI Hazard ratio 95% CI P-value
GFR (mL/min/1.73 m2)
≥90 820 5087 11 2.6 1.4–4.7 1.00 –
60–90 741 5330 23 4.8 3.2–7.2 1.95 0.95–4.01
30–60 564 4018 94 21.4 17.7–25.7 10.6 5.70–19.9
15–30 114 497 81 81.3 72.2–88.8 80.4 42.8–151.0
<15 44 43 43 –a –a 679.9 340.3–1358.3 <0.001 for trend
Histological grade at initial renal biopsy
Grade I 517 3232 13 4.7 2.7–8.2 1.00 –
Grade II 702 4805 29 6.2 4.3–9.0 1.51 0.79–2.91
Grade III 693 4802 105 19.7 16.5–23.5 5.48 3.08–9.75
Grade IV 212 1153 89 48.4 41.1–56.3 19.2 10.7–34.4 <0.001 for trend
ESRD, end-stage renal disease; CI, confidence interval; GFR, glomerular filtration rate.
aAll patients reached ESRD or were censored before 120 months.
ratios. Male sex, advanced age, earlier renal biopsy, higher
systolic and diastolic blood pressure, more severe protein-
uria,lowerserumtotalproteinandalbumin,lowerGFRand
higherhistologicalgradeweresignificantlyassociatedwith
the risk of ESRD. On the other hand, patients whose initial
clinicalmanifestationwasmacrohaematuriahadfavourable
renal outcomes. Mild haematuria, 1–29 red blood cells per
high-power field (RBCs/HPF), showed a higher risk than
severe haematuria, ≥30 RBCs/HPF (18.2% versus 12.3%).
There were no remarkable differences in risk between his-
tological grade I and II (4.7% versus 6.2%).
Multivariable analysis and development of the scoring
system
Results of the multivariable analysis for the risk of ESRD
by factors are summarized in Table 3. Family histories of
chronic renal failure and chronic glomerulonephritis were
significant factors for predicting renal outcome in the mul-
tivariable model. Instead, initial manifestation of macro-
haematuria and earlier renal biopsy were no longer sig-
nificant. Male sex, higher systolic blood pressure, more
severe proteinuria, mild haematuria, hypoalbuminaemia,
lower GFR and higher histological grade were associated
with the development of ESRD. Patients aged less than
30 years were at higher risk in the multivariable model,
whereas an upward trend in the hazard ratio with advancing
age was found in the univariate analysis.
Based on these analyses, we composed a scoring sys-
tem to estimate a 10-year risk of ESRD. Because the pres-
ence of family histories of chronic renal failure and chronic
glomerulonephritis had no significant univariate relation-
ships with ESRD and the area under the ROC curve of
the model was rather smaller than that without these vari-
ables, they were removed from the final prediction scheme.
Table 4(a) lists the scores of individual prognostic fac-
tors. The sum of individual scores can then be converted
into the corresponding estimated risk using those shown in
Table 3. Hazard ratios of end-stage renal disease by major baseline de-
mographic and clinical factors using multivariable analysis
Hazard ratio 95% CI P-value
Male sex 1.73 1.25–2.38 0.001
Age <30 years 3.41 2.13–5.46 <0.001
Family history of chronic 2.49 1.20–5.17 0.015
renal failure
Family history of chronic 2.07 1.07–4.02 0.031
glomerulonephritis
Systolic blood pressure
(mmHg)
≤130 1.00 – –
131–160 1.46 1.06–2.00 0.020
>160 3.13 1.63–6.03 0.001
Urine protein
(−), (±)1 . 0 0 – –
(+) 3.41 1.29–9.06 0.014
(++) 8.12 3.22–20.5 <0.001
(+++) 12.4 4.91–31.3 <0.001
Mild haematuria 2.34 1.64–3.33 <0.001
(1–29 RBC/HPF)
Serum albumin <4.0 g/dL 1.94 1.41–2.66 <0.001
Glomerular filtration rate
(mL/min/1.73 m2)
≥90 1.00 – –
60–90 2.31 0.98–5.41 0.055
30–60 9.46 4.12–21.7 <0.001
15–30 76.2 31.6–183.7 <0.001
<15 880.3 326.9–2370.5 <0.001
Histological grade III or IV 1.70 1.12–2.56 0.012
at initial renal biopsy
CI, confidence interval; RBC/HPF, red blood cells per high-power field.
Table 4(b). The baseline survivor function was estimated as
0.9993504 at 10 years.
Evaluation of the scoring system
The renal survival curves according to the estimated 10-
year risk are shown in Figure 1. The prognostic score
successfully classified the patients by risk. Those with an3072 M. Goto et al.
Table 4. Scores to estimate the risk of end-stage renal disease (ESRD)
by demographic and clinical factors (a) and the estimated 10-year risk of
ESRD by total score (b)
(a) Scores of individual prognostic
factors
(b) Estimated 10-year risk of
ESRD by total score
Estimated 10-year
Score Total score risk of ESRD (%)
Male sex 6 0–26 0–1
Age <30 years 12 27–43 1–5
Systolic blood pressure 44–50 5–10
(mmHg) 51–58 10–20
≤130 0 59–63 20–30
131–160 4 64–70 30–50
>160 11 71–75 50–70
Urine protein 76–82 70–90
(−), (±) 0 83–140 90–100
(+)1 2
(++)2 1
(+++)2 5
Mild haematuria 8
(1–29 RBC/HPF)
Serum albumin <4.0 g/dL 7
Glomerular filtration rate
(mL/min/1.73 m2)
≥90 0
60–90 7
30–60 22
15–30 42
<15 66
Histological grade III or IV 5
RBC/HPF, red blood cells per high-power field.
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Fig. 1. Renal survival curves by estimated 10-year risk of end-stage renal
disease. Patients were categorized into four groups according to the esti-
matedrisk:low(0–4.9%,n=1007),moderate(5.0–19.9%,n=365),high
(20.0–49.9%, n = 154) and very high (50.0–100%, n = 135). Numbers of
patients at risk were 1661, 1430, 1216, 1005, 706 and 537 at 0, 2, 4, 6, 8
and 10 years, respectively.
estimated risk of 0–4.9% (score, 0–43), 5.0–19.9% (44–
58), 20.0–49.9% (59–70) and 50.0–100% (71 or more) had
an actual cumulative incidence of ESRD in 10 years of
1.7% (95% CI, 0.86–3.5), 8.3% (5.4–12.5), 36.7% (28.4–
46.5) and 85.5% (78.0–91.5), respectively. This indicated a
good agreement between the estimated and observed risks.
Furthermore, the area under the ROC curve of this predic-
tionmodelreached0.942(95%CI,0.925–0.958)(Figure2).
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Fig. 2. The receiver-operating characteristic curve for predicting end-
stage renal disease within 10 years by current scoring system.
Even when the prognostic scores were developed us-
ing derivation samples randomly selected from all partici-
pants,theestimated10-yearcumulativeincidenceofESRD
well predicted the observed ones in the remaining valida-
tion sample. The median values of observed 10-year inci-
dencewere2.2%(IQR,1.5–3.0%),9.2%(7.4–11.8),34.3%
(30.4–38.6) and 83.4% (76.7–87.1) in patients with an es-
timated risk of 0–4.9, 5.0–19.9, 20.0–49.9 and 50.0–100%,
respectively. The median of the corresponding area under
the ROC curve (0.935; IQR, 0.924–0.944) was comparable
with the area in the full dataset (0.942).
Discussion
Based on a large-scale cohort study, we described the prog-
nostic indicators for IgAN and developed a scoring sys-
tem for estimating the ESRD risk within 10 years. Male
sex, age less than 30 years, the presence of family histo-
ries of chronic renal failure and chronic glomerulonephri-
tis, higher systolic blood pressure, more severe protein-
uria, mild haematuria, hypoalbuminaemia, lower GFR and
higher histological grade were related to the risk. The
prognostic score comprising eight variables significant
in both univariable and multivariable models successfully
classified patients according to their ESRD risk, and the
accuracy in predicting the ESRD was excellent.
We could establish a much simpler scoring system than
the former one based on the 7-year follow-up data [10] by
reducing the number of choices of each scoring item. Nev-
ertheless, we did not compromise with the predictability;
the areas under the ROC curve estimating ESRD risk rather
increasedby0.003from0.939(95%CI,0.921–0.958)[10].
Male sex was a significant risk factor for ESRD in the
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the former scoring. It would be attributable to the overesti-
mationofthewomen’skidneyfunctionbasedonlyonserum
creatinine in our previous analysis. We could estimate GFR
more elaborately based on serum creatinine, as well as age
and gender in the current analysis, which made our under-
standing of the relationships between each predictor much
simpler. One of the reasons for the increase in the relative
weight of the age variable in the current model compared
to that in the previous one is also this overestimation of the
baseline renal function among the older patients. Contrary
to the age variable, the prognostic value of the histologi-
cal grade at initial renal biopsy declined by extending the
follow-up period.
We selected serum albumin in the current multivariable
model, instead of serum total protein in the prior one, be-
cause both AIC and BIC of the model were substantially
decreasedbyreplacingserumtotalproteinwithserumalbu-
min. This replacement seems rational from the pathophys-
iological viewpoint that glomerular proteinuria is mainly
composed of albumin.
In the multivariable analysis, we found that the pres-
ence of family histories of chronic renal failure and chronic
glomerulonephritis were associated with the development
of ESRD. Several genetic factors are considered to be
associated with the prognosis of IgAN. For example, some
genesrelatedtotherenin–angiotensinsystemaresuggested
to have prognostical importance [15–17]. A report from
China suggested an association between the polymorphism
of the megsin gene, a kidney-specific serine protease in-
hibitor, and the progression of IgAN [18]. Furthermore,
familial IgAN was reported to have a worse prognosis in
an observational epidemiological study [19]. Nevertheless,
the influences of genetic inheritance are still in controversy
and have not reached a consensus [16,20–22].
In virtue of the current scoring system, clinicians can
quantitatively estimate ESRD risks during 10 years of
follow-up of IgAN patients by summing up only eight inte-
gersyieldedfromtheroutineclinico-pathologicaldata.The
validated, multivariable regression-based model should aid
medicaldecisionmakingaboutpatientswithbiopsy-proved
IgAN. Patients judged to be at higher risk can receive more
frequent monitoring and more intensive treatment, whereas
patients estimated to be at lower risk can be reassured and
given less intensive care.
Given the nature of the observational design and
the insufficient information regarding treatment, a clear
evaluation of the influence of therapy is beyond the scope
of the current analysis. Even though the optimal approach
to the treatment of IgAN is uncertain, some strategies have
beenprovedeffectiveinreducingproteinuriaandtherateof
disease progression through the accumulation of evidence
during the last decade. According to both observational
studies [23,24] and randomized trials [25–27], ACEi and
angiotensinIIreceptorblockershaveadefiniteroleintreat-
ing IgAN, particularly of the hypertensive and proteinuric
forms. A review supports the use of corticosteroids and
other immunosuppressive agents in reducing proteinuria or
preventing progression to ESRD [28]. Increasing attention
has been paid to the role of tonsillectomy for the long-term
prognosis of IgAN [29,30]. The estimated risk of ESRD
by the current scoring system, therefore, might be attenu-
ated for patients properly treated in the latter portion of the
observation interval.
Some other potential limitations of the current analysis
must be acknowledged. First, because the data on 24-h
urinary protein excretion were not available for two-thirds
of the patients and those on urinary creatinine were not
collected, we had to assess proteinuria with simple dipstick
urine test results. However, the semiquantified proteinuria
was reproducible and considerably correlated with the 24-h
urinary excretion of protein [10,31], and the predictability
of the current scoring system was excellent. Feasibility in
clinical settings would override theoretical propriety. From
apragmaticstandpoint,cliniciansshouldaverageortakethe
median of the results of several urinalyses when applying
thisscoringsystem.Second,thecurrentscoringsystemwas
developed among Japanese patients, and the applicability
of the results to other races was not verified. Another study
adjusting for racial differences in serum creatinine, which
was a main determinant of GFR in the estimation equation,
would assure the generalizability of the current scoring
system.
In summary, the present study revealed that male sex,
agelessthan30years,familyhistoriesofchronicrenalfail-
ure and chronic glomerulonephritis, hypertension, protein-
uria, mild haematuria, hypoalbuminaemia, low GFR and
advanced histological changes increased the risk of ESRD
in IgAN patients. The ESRD prediction score based on a
multivariable model was sufficiently valid and will serve as
a useful tool for clinicians treating IgAN patients.
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Abstract
Background. In Fabry disease, storage of globotriaosylce-
ramide (Gb3) in arterial walls is one of the main patho-
genetic factors that are thought to underlie the clinical
manifestations of the disease. Abnormalities of the ves-
sel wall, haemodynamics and pro- and anticoagulant fac-
tors may play a role, though the exact pathophysiology is
incompletely understood. In this study, we try to clarify
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